In 2023, Kridin et al. [80] compared in a global population-based cohort the probability of complications of infections in psoriatic patients treated with IL-23 inhibitors (risankizumab, guselkumab, and tildrakizumab) and in those treated with TNF inhibitors (adalimumab, infliximab, etanercept, infliximab and certolizumab pegol). This evidence concerns the gene IL23A and infection.